CLINICAL_TRIALS
trial_result
· 2025-05-04
Clinical Trial Update: Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms [Phase 2]
Summary
Phase 2 results for coversin in paroxysmal nocturnal hemoglobinuria patients who are resistant to eculizumab due to C5 polymorphisms; the trial is completed and…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AKARI Therapeutics | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Status: COMPLETED | Results posted: 2025-05-04